Jefferies rates Basilea at buy

Basilea Pharmaceutica was rated at buy by Jefferies & Co., Inc. analyst Robin Campbell as the company remains on a fast track to becoming an integrated specialty biotech company. Ceftobiprole, its enhanced-activity broad-spectrum cephalosporin, has shown encouraging results from its first phase 3 trial. Shares of the Basel, Switzerland, pharmaceutical company were unchanged at CHF 181.00 on volume of 121,721 shares versus the three-month running average of 25,921 shares. (Swiss: BSLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.